Conduit Pharmaceuticals Inc.
CDT
$0.9101
-$0.1599-14.94%
| Weiss Ratings | CDT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E- | |||
| Rating Factors | CDT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Very Weak | |||
| Beta / Standard Deviation | CDT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.37 | |||
| Price History | CDT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 21.85% | |||
| 30-Day Total Return | -24.16% | |||
| 60-Day Total Return | -89.29% | |||
| 90-Day Total Return | -91.47% | |||
| Year to Date Total Return | -87.98% | |||
| 1-Year Total Return | -99.71% | |||
| 2-Year Total Return | -99.91% | |||
| 3-Year Total Return | -99.91% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -99.69% | |||
| 52-Week Low % Change | 109.80% | |||
| Price | CDT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $350.00 | |||
| 52-Week Low Price | $0.51 | |||
| 52-Week Low Price (Date) | Apr 09, 2025 | |||
| 52-Week High Price (Date) | May 07, 2024 | |||
| Valuation | CDT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 7.13M | |||
| Enterprise Value | 14.03M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -21.85 | |||
| Earnings Per Share Growth | 141.74% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -0.22 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.91 | |||
| Enterprise Value/EBITDA (TTM) | -1.44 | |||
| Enterprise Value/EBIT | -0.86 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | CDT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.12M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CDT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | (646)-491-9132 | |||
| Address | 4581 Tamiami Trail North Naples, FL 34103 | |||
| Website | www.conduitpharma.com | |||
| Country | United States | |||
| Year Founded | 2019 | |||
| Profitability | CDT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | CDT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -178.34% | |||
| Return on Equity | -- | |||
| Income Statement | CDT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -9.74M | |||
| EBIT (TTM) | -16.29M | |||
| Net Income (TTM) | -17.80M | |||
| Net Income Avl. to Common (TTM) | -17.80M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -1,082.04% | |||
| EPS Diluted (TTM) | -21.85 | |||
| EPS Diluted Growth (Q YOY) | 41.25% | |||
| Balance Sheet | CDT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 554.00K | |||
| Cash Per Share (Q) | $0.50 | |||
| Total Current Assets (Q) | 2.72M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -6.79M | |||
| Current Ratio (Q) | 0.253 | |||
| Book Value Per Share (Q) | -$4.91 | |||
| Total Assets (Q) | 4.19M | |||
| Total Current Liabilities (Q) | 10.74M | |||
| Total Debt (Q) | 7.46M | |||
| Total Liabilities (Q) | 10.99M | |||
| Total Common Equity (Q) | -6.79M | |||
| Cash Flow | CDT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -43.00K | |||
| Cash from Financing (TTM) | 6.07M | |||
| Net Change in Cash (TTM) | -3.67M | |||
| Levered Free Cash Flow (TTM) | -893.90K | |||
| Cash from Operations (TTM) | -9.68M | |||
